2011 Alzheimer's disease facts and figures - PubMed (original) (raw)
2011 Alzheimer's disease facts and figures
Alzheimer's Association. Alzheimers Dement. 2011 Mar.
Abstract
Alzheimer's disease (AD) is the sixth leading cause of all deaths in the United States and is the fifth leading cause of death in Americans aged ≥65 years. Although other major causes of death have been on the decrease, deaths because of AD have been rising dramatically. Between 2000 and 2008 (preliminary data), heart disease deaths decreased by 13%, stroke deaths by 20%, and prostate cancer-related deaths by 8%, whereas deaths because of AD increased by 66%. An estimated 5.4 million Americans have AD; approximately 200,000 people aged <65 years with AD comprise the younger-onset AD population. Every 69 seconds, someone in America develops AD; by 2050, the time is expected to accelerate to every 33 seconds. Over the coming decades, the baby boom population is projected to add 10 million people to these numbers. In 2050, the incidence of AD is expected to approach nearly a million people per year, with a total estimated prevalence of 11 to 16 million people. Dramatic increases in the numbers of "oldest-old" (those aged ≥85 years) across all racial and ethnic groups will also significantly affect the numbers of people living with AD. In 2010, nearly 15 million family and other unpaid caregivers provided an estimated 17 billion hours of care to people with AD and other dementias, a contribution valued at more than 202billion.Medicarepaymentsforservicestobeneficiariesaged≥65yearswithADandotherdementiasarealmost3timeshigherthanforbeneficiarieswithouttheseconditions.Totalpaymentsin2011forhealthcare,long−termcare,andhospiceservicesforpeopleaged≥65yearswithADandotherdementiasareexpectedtobe202 billion. Medicare payments for services to beneficiaries aged ≥65 years with AD and other dementias are almost 3 times higher than for beneficiaries without these conditions. Total payments in 2011 for health care, long-term care, and hospice services for people aged ≥65years with AD and other dementias are expected to be 202billion.Medicarepaymentsforservicestobeneficiariesaged≥65yearswithADandotherdementiasarealmost3timeshigherthanforbeneficiarieswithouttheseconditions.Totalpaymentsin2011forhealthcare,long−termcare,andhospiceservicesforpeopleaged≥65yearswithADandotherdementiasareexpectedtobe183 billion (not including the contributions of unpaid caregivers). This report provides information to increase understanding of the public health effect of AD, including incidence and prevalence, mortality, health expenditures and costs of care, and effect on caregivers and society in general. The report also examines the current state of AD detection and diagnosis, focusing on the benefits of early detection and the factors that present challenges to accurate diagnosis.
Copyright © 2011 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Similar articles
- 2010 Alzheimer's disease facts and figures.
Alzheimer's Association. Alzheimer's Association. Alzheimers Dement. 2010 Mar;6(2):158-94. doi: 10.1016/j.jalz.2010.01.009. Alzheimers Dement. 2010. PMID: 20298981 - 2012 Alzheimer's disease facts and figures.
Alzheimer's Association. Alzheimer's Association. Alzheimers Dement. 2012;8(2):131-68. doi: 10.1016/j.jalz.2012.02.001. Alzheimers Dement. 2012. PMID: 22404854 - 2009 Alzheimer's disease facts and figures.
Alzheimer's Association. Alzheimer's Association. Alzheimers Dement. 2009 May;5(3):234-70. doi: 10.1016/j.jalz.2009.03.001. Alzheimers Dement. 2009. PMID: 19426951 - The costs of Alzheimer's disease and the value of effective therapies.
Stefanacci RG. Stefanacci RG. Am J Manag Care. 2011 Nov;17 Suppl 13:S356-62. Am J Manag Care. 2011. PMID: 22214393 Review. - Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective.
Rice DP, Fillit HM, Max W, Knopman DS, Lloyd JR, Duttagupta S. Rice DP, et al. Am J Manag Care. 2001 Aug;7(8):809-18. Am J Manag Care. 2001. PMID: 11519239 Review.
Cited by
- Anti-Alzheimer's Potency of Rich Phenylethanoid Glycosides Extract from Marrubium vulgare L.: In Vitro and In Silico Studies.
Emam M, El-Newary SA, Aati HY, Wei B, Seif M, Ibrahim AY. Emam M, et al. Pharmaceuticals (Basel). 2024 Sep 27;17(10):1282. doi: 10.3390/ph17101282. Pharmaceuticals (Basel). 2024. PMID: 39458923 Free PMC article. - Assessing the Potential of 1,2,3-Triazole-Dihydropyrimidinone Hybrids Against Cholinesterases: In Silico, In Vitro, and In Vivo Studies.
Gastalho CM, Sena AM, López Ó, Fernández-Bolaños JG, García-Sosa AT, Pereira F, Antunes CM, Costa AR, Burke AJ, Carreiro EP. Gastalho CM, et al. Int J Mol Sci. 2024 Oct 17;25(20):11153. doi: 10.3390/ijms252011153. Int J Mol Sci. 2024. PMID: 39456935 Free PMC article. - Relationship Between Oral Motor and Cognitive Function in Community-Dwelling Korean Older Adults: A Cross-Sectional, Observational Study.
Jung NH. Jung NH. Healthcare (Basel). 2024 Oct 21;12(20):2097. doi: 10.3390/healthcare12202097. Healthcare (Basel). 2024. PMID: 39451511 Free PMC article. - Components in SLPE Alleviate AD Model Nematodes by Up-Regulating Gene gst-5.
Zhao P, Wang Z, Liao S, Liao Y, Hu S, Qin J, Zhang D, Yan X. Zhao P, et al. Int J Mol Sci. 2024 Sep 23;25(18):10188. doi: 10.3390/ijms251810188. Int J Mol Sci. 2024. PMID: 39337674 Free PMC article. - Porphyromonas gingivalis promote microglia M1 polarization through the NF-кB signaling pathway.
Li X, Yao C, Lan D, Chen Y, Wang Y, Qi S. Li X, et al. Heliyon. 2024 Jul 26;10(15):e35340. doi: 10.1016/j.heliyon.2024.e35340. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39170188 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical